Accenture, JSR and NTT Begin Work on a Proof-of-Concept for a Smart Industrial Complex
Accenture (NYSE: ACN), JSR Corporation, a chemicals manufacturer headquartered in Japan, and Nippon Telegraph and Telephone Corporation (NTT), one of the world's largest telecommunications services providers headquartered in Japan are embarking on a proof-of-concept project at JSR’s plant in Chiba Prefecture designed to improve worker productivity and safety in smart industrial complexes that is technology driven and analytics led.
The plan is to develop a ‘connected worker’ analytics platform leveraging smart sensors and wireless technology to automatically collect and analyze unstructured data – such as motion images and sound recordings from plant operation management and maintenance tasks performed by experienced workers at the Chiba Plant. The cross-company teams will work together to combine these insights with machine data from distributed control systems, and to develop a solution that will help users make more informed decisions using a machine learning algorithm in real-time. The goal is to convert the tacit knowledge of experienced workers into explicit knowledge, and transfer it to less experienced workers.
The proof-of-concept will integrate JSR’s insights in operation management and maintenance tasks, artificial intelligence “corevo®”(*) of NTT Group including NTT Advanced Technology Corporation, along with industry-leading digital transformation expertise and Industrial Internet of Things (IIoT) capabilities of Accenture Strategy. This proof-of-concept is based on the ideas of open innovation which is vital for a smart industrial complex, and one that integrates key capabilities from the three companies into one seamless digital transformation plan.
A smart industrial complex has the potential to improve knowledge transfer and address safety issues. This is a major priority for the Ministry of Economy, Trade and Industry, which recently announced a new Japanese industry plant safety policy, the Super Certified Plant System. The industry needs to address safety issues and establish stable, continuous operation, but faces additional challenges: a shrinking talent pool of experienced workers due to an aging workforce and investment spending constraints for IT solutions as spending has been required in recent years for safety solutions such as explosion prevention.
“The chemicals industry will face major transformation when digitalization makes it possible to detect signs of equipment abnormalities and predict product supply and demand,” said Mitsunobu Koshiba, representative director and president, JSR. “Harnessing the innovation of NTT and Accenture, we will promote a smart industrial complex and contribute to enhancing the competitive edge of Japan’s chemicals industry.”
“We are accelerating NTT’s transition to its new business model, B2B2X, and are committed to offering value-added services by collaborating with companies in different fields to extend our offerings,” said Jun Sawada, senior executive vice president, NTT. “This initiative helps establish a smart industrial complex and future growth of the chemicals industry in Japan, and it also embodies a business model for NTT that maximizes the potential of ICT.”
Connected worker technology is one element of what Accenture refers to as Industry X.0 - the digital reinvention of industry. It is when businesses use advanced digital technologies to transform their core operations, their worker and customer experiences and ultimately their business models.
“Digital disruption presents unparalleled growth and new value creation opportunities for Japan’s chemicals industry, especially when viewed through the Industry X.0 prism,” said Atsushi Egawa, representative director and president of Accenture Japan. “The deep chemicals industry expertise, and digital transformation and IIoT capabilities Accenture Strategy brings to the PoC will help embrace digital disruption in addition to improving plant productivity and worker safety. Turning this solution into a practical technology driven and analytics led business model will help us showcase that Industry X.0 can deliver new levels of efficiency in R&D, engineering, production, manufacturing and business support through integrated systems, processes, sensors and new intelligence.”
About JSR Corporation
JSR Corporation (formerly 'Japan Synthetic Rubber Co., Ltd.') was established in 1957 for domestic production of synthetic rubbers. Since then, JSR has continuously expanded its business to emulsions and plastics, and from the late 1970s, expanded to other materials for the semiconductor, flat panel display, and optical materials fields by leveraging our proprietary polymer technologies. In addition to the Petrochemicals and Fine Chemicals fields, JSR works on the Life Sciences field as one of its new business pillars to expand its profits.
About Nippon Telegraph and Telephone Corporation
NTT Group delivers advanced technology and innovative solutions in networking, software communications, and cloud computing that help transform businesses, governments and societies around the world. NTT Group will deliver convenient, enriched and reliable services to support customers as a “Value Partner” that its customers will continue to select. Today, 88% of Fortune 100 companies rely on NTT Group as their business partner. NTT Group generates over $105 billion in annual revenues, has over 240 data centers and employs more than 275,000 professionals working in 88 countries and regions.
Accenture is a leading global professional services company, providing a broad range of services and solutions in strategy, consulting, digital, technology and operations. Combining unmatched experience and specialized skills across more than 40 industries and all business functions - underpinned by the world’s largest delivery network - Accenture works at the intersection of business and technology to help clients improve their performance and create sustainable value for their stakeholders. With more than 411,000 people serving clients in more than 120 countries, Accenture drives innovation to improve the way the world works and lives. Visit us at www.accenture.com.
Accenture Strategy operates at the intersection of business and technology. We bring together our capabilities in business, technology, operations and function strategy to help our clients envision and execute industry-specific strategies that support enterprise wide transformation. Our focus on issues related to digital disruption, competitiveness, global operating models, talent and leadership help drive both efficiencies and growth. For more information, follow @AccentureStrat or visit www.accenture.com/strategy.
Nobuhiko Kuwashima, + 81 3 6218 3517
Nippon Telegraph and Telephone Corporation
Shigeo Masuda, + 81 45 330 7157
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an